why choose us

First received: September 14, 2022

Clinical Trial: A Study of TAK-625 for the Treatment of Alagille Syndrome (ALGS)

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Alagille Syndrome (ALGS)

Study Type: INTERVENTIONAL


Official Title: An Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of TAK-625 in the Treatment of Subjects With Alagille Syndrome

Brief Summary: The main aim of the study is to check if TAK-625 improves symptoms of Alagille Syndrome (ALGS), side effect from the study treatment or TAK-625, and how much TAK-625 stays in their blood over time.This will help the study sponsor (Takeda) to work out the best dose to give people in the future.The participants will be treated with TAK-625 for up to the end of study (about 34 months).Participants will visit their study clinic 9 times from the start of study.After 9 times visits, participants will visit their study…

Read more